NextCell Pharma publishes its Interim Report 4 2024/2025

Fourth Quarter (2025-06-01 to 2025-08-31)

• Operating income amounted to 2,522 (1,696) TSEK, of which Cellaviva contributed 2,600 (1,643) TSEK.
• Net sales amounted to 2,600 (1,643) TSEK.
• Profit/loss after financial items amounted to -8,481 (-13,249) TSEK.
• Earnings per share* were -0.08 (-0.22) SEK.
• Cash and cash equivalents amounted to 38,723 (49,970) TSEK.
• Equity ratio** amounted to 86 (83) percent.

Twelve Months (2024-09-01 to 2025-08-31)

• Operating income amounted to 11,065 (11,278) TSEK, of which Cellaviva contributed 10,937 (10,665) TSEK.
• Net sales amounted to 10,937 (10,665) TSEK.
• Profit/loss after financial items amounted to -34,992 (-41,960) TSEK.
• Earnings per share* were -0.46 (-1.03) SEK.

*Earnings per share: Net result for the period divided by the average number of shares. The average number of shares for the fourth quarter of 2024/2025: 109,746,641 (59,979,085) shares. The average number of shares for the first twelve months  of 2024/2025: 76,412,199 (40,814,386) shares. The number of shares in NextCell as of 31 August 2025: 111,392,959 (73,091,327) shares.
**Equity ratio: Shareholders’ equity as a percentage of total assets.

Significant events and news during the fourth quarter

• At the beginning of June, the Company announced the outcome of the exercise of TO2 and resolved on directed share issues to guarantors, Through the exercise of the Warrants and the Directed Issue, the Company will receive a total of approximately SEK 36.6 million before deduction of issue costs. Furthermore, the Board of Directors has resolved on a set-off issue of 1,742,100 shares to the guarantors for payment of the guarantee fee.
   
• The Company announced in early June that all patients in the ongoing ProTrans-Young clinical study had been treated. A milestone that marks the completion of dosing in the company's largest clinical study to date. ProTrans-Young is evaluating the safety and efficacy of the company's lead cell therapy candidate, ProTrans, for the treatment of children and adolescents with newly diagnosed type 1 diabetes.Cell and Gene Therapy (ISCT).
   
• In Mid-July the company summoned to an Extraordinary General Meeting in order to change the company's fiscal year to be aligned with the calendar year.

• At the end of August, NextCell announced that the Extraordinary General Meeting had resolved to amend the Articles of Association to reschedule the financial year to be 1 January – 31st December.

Significant events and news after the reporting period

• At the beginning of September, NextCell announced that the company’s CFO Patrik Fagerholm is leaving his position and that the recruitment process to find a replacement has begun.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 30-10-2025 07:30 CET.